InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,440.00
(
2.13%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
-1.03%
)
Bitcoin
62,611.68
(
5.90%
)
Post# of 30990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

knuts4oe

Send PM Follow Ignore
Followers 4
Posts 682
Boards Moderated 0
Alias Born 06/26/2013

knuts4oe

Re: nep2134 post# 28122

Saturday, 04/15/2017 10:02:10 AM

Saturday, April 15, 2017 10:02:10 AM

Post# of 30990
My reaction is that you are not being realistic. Roskamp has done three mouse studies, peer reviewed and published, in which the peer reviewers, apparently impressed with the results, recommended additional studies.

The reaction by other medical researchers? ZILCH! No one believes it! Not even the support groups for AD, Hashimoto's Thyroiditis, or Multiple Sclerosis, which were the object of the three studies.

Again, some success with Nilvad and AD, may lead to the recognition that Anatabine desperately needs.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up